Read our latest updates & insights

Bloomberg Law reports on the ongoing US Court of Appeals for the Federal Circuit dispute between Genentech and Amgen regarding bevacizumab. In a hearing on 3 June 2020, Genentech asked the Court to prevent Amgen selling its biosimilar bevacizumab Mvasi® to new patients, des...

Significant biosimilar activities this week include
25 May 20 | The American Journal of Managed Care reported two cost savings studies presented at a virtual meeting of the International Society for Pharmacoeconomics and Outcomes Research.  The studies, which were spo...

LiveMint reported that Aurobindo Pharma announced it would sell its biosimilars business to its wholly owned subsidiary, CuraTeQ Biologics in 2019/20 Q4 earnings call.

Eli Lilly announced that the FDA has approved Taltz® (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis.

Henlius Biotech announces it has received a positive CHMP opinion, recommending marketing authorisation for HLX02 (proposed trastuzumab biosimilar).

Fresenius Kabi announces it has signed an agreement with Medac to cooperate in Germany in the area of treatments for rheumatic illnesses. From 01 June 2020, Medac’s sales representatives will be able to offer Fresenius Kabi’s adalimumab biosimilar Idacio. Medac ...

The WHO certifies Celltrion’s Truxima® (rituximab) in its prequalification program. This program assesses clinical and other data related to biosimilars, and aims to guide low-income countries in their selection of medicines, vaccines and technologies for national pro...

Pulse News reported that AProgen had doubled its production capacity with the addition of two new perfusion production lines, increasing total output capacity to 240,000 litres of culture fluid per cycle. AProgen currently has adalimumab, infliximab, trastuzumab, etanercept...